Introducing S.C.O.P.E.™ (Schizophrenia Clinical Outcome Scenarios and Patient-Provider Engagement), an Interactive Digital Platform to Educate Healthcare Professionals on Schizophrenia Care

Overview

Journal Neuropsychiatr Dis Treat

Publisher Dove Medical Press

Specialty Psychiatry

Date 2024 Oct 24

PMID 39444923

Authors

Christoph U Correll

Jose M Rubio

Leslie Citrome

Marko A Mychaskiw

Stephen Thompson

Kelli R Franzenburg

Mark Suett

Sameer Kotak

John M Kane

Affiliations

Soon will be listed here.

Abstract

Despite evidence of benefits beyond those of oral antipsychotics, long-acting injectable antipsychotics (LAIs) are underused in schizophrenia treatment. Underuse may be partially a result of misconceptions held by some healthcare professionals (HCPs) pertaining to LAIs. A panel of four experts convened between January 2022 and May 2022 to identify these misconceptions, and example cases or scenarios were created to illustrate common clinical situations relevant to these beliefs. Ultimately, an online platform and heuristic tool, Schizophrenia Clinical Outcome Scenarios and Patient-Provider Engagement (S.C.O.P.E.™), was developed to help prescribing clinicians and other HCPs better understand common clinical dilemmas, as well as the place for LAIs in schizophrenia treatment. Three main misconceptions related to the use of LAIs to treat schizophrenia were identified and included "physicians/providers know when patients are nonadherent", "patients do not accept/want LAI treatment", and "LAIs are only appropriate for patients who have demonstrated nonadherence". All misconceptions are refuted by current evidence and were used to develop clinical scenarios with questions to consider when patients present to various sites of care for treatment. These cases are presented on the S.C.O.P.E. educational platform. The platform also includes videos designed to help non-prescribing HCPs and mental health professionals address patient/caregiver concerns and to communicate LAI benefits. In addition, S.C.O.P.E. provides a section with information about each LAI that is currently FDA approved in the United States for the treatment of schizophrenia, to help familiarize HCPs with characteristics of LAIs. S.C.O.P.E. is an educational tool designed for HCPs to help improve their understanding of how to manage common clinical dilemmas in the treatment of people with schizophrenia, to clarify the role of LAIs in medication management, and to increase understanding of the characteristics of available LAIs. S.C.O.P.E. also aims to improve care in schizophrenia by facilitating increased awareness to patients and caregivers.

References

Bareis N, Olfson M, Wall M, Stroup T . Variation in Psychotropic Medication Prescription for Adults With Schizophrenia in the United States. Psychiatr Serv. 2021; 73(5):492-500. PMC: 8964836. DOI: 10.1176/appi.ps.202000932. View

Cahling L, Berntsson A, Broms G, Ohrmalm L . Perceptions and knowledge of antipsychotics among mental health professionals and patients. BJPsych Bull. 2017; 41(5):254-259. PMC: 5623883. DOI: 10.1192/pb.bp.116.055483. View

Fitzgerald H, Shepherd J, Bailey H, Berry M, Wright J, Chen M . Treatment Goals in Schizophrenia: A Real-World Survey of Patients, Psychiatrists, and Caregivers in the United States, with an Analysis of Current Treatment (Long-Acting Injectable vs Oral Antipsychotics) and Goal Selection. Neuropsychiatr Dis Treat. 2021; 17:3215-3228. PMC: 8544790. DOI: 10.2147/NDT.S330936. View

Lopez L, Shaikh A, Merson J, Greenberg J, Suckow R, Kane J . Accuracy of Clinician Assessments of Medication Status in the Emergency Setting: A Comparison of Clinician Assessment of Antipsychotic Usage and Plasma Level Determination. J Clin Psychopharmacol. 2017; 37(3):310-314. DOI: 10.1097/JCP.0000000000000697. View

Sajatovic M, Ross R, Legacy S, Correll C, Kane J, DiBiasi F . Identifying patients and clinical scenarios for use of long-acting injectable antipsychotics - expert consensus survey part 1. Neuropsychiatr Dis Treat. 2018; 14:1463-1474. PMC: 5997124. DOI: 10.2147/NDT.S167394. View

Gallego J, Bonetti J, Zhang J, Kane J, Correll C . Prevalence and correlates of antipsychotic polypharmacy: a systematic review and meta-regression of global and regional trends from the 1970s to 2009. Schizophr Res. 2012; 138(1):18-28. PMC: 3382997. DOI: 10.1016/j.schres.2012.03.018. View

Leucht S, Tardy M, Komossa K, Heres S, Kissling W, Salanti G . Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. Lancet. 2012; 379(9831):2063-71. DOI: 10.1016/S0140-6736(12)60239-6. View

Kane J, Garcia-Ribera C . Clinical guideline recommendations for antipsychotic long-acting injections. Br J Psychiatry Suppl. 2009; 52:S63-7. DOI: 10.1192/bjp.195.52.s63. View

Howes O, McCutcheon R, Agid O, de Bartolomeis A, van Beveren N, Birnbaum M . Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology. Am J Psychiatry. 2016; 174(3):216-229. PMC: 6231547. DOI: 10.1176/appi.ajp.2016.16050503. View

10.

Kane J, Chen A, Lim S, Mychaskiw M, Tian M, Wang Y . Early versus late administration of long-acting injectable antipsychotic agents among patients with newly diagnosed schizophrenia: an analysis of a commercial claims database. Int Clin Psychopharmacol. 2023; 38(4):240-248. PMC: 10234320. DOI: 10.1097/YIC.0000000000000452. View

11.

Correll C, Solmi M, Croatto G, Schneider L, Rohani-Montez S, Fairley L . Mortality in people with schizophrenia: a systematic review and meta-analysis of relative risk and aggravating or attenuating factors. World Psychiatry. 2022; 21(2):248-271. PMC: 9077617. DOI: 10.1002/wps.20994. View

12.

Correll C, Agid O, Crespo-Facorro B, de Bartolomeis A, Fagiolini A, Seppala N . A Guideline and Checklist for Initiating and Managing Clozapine Treatment in Patients with Treatment-Resistant Schizophrenia. CNS Drugs. 2022; 36(7):659-679. PMC: 9243911. DOI: 10.1007/s40263-022-00932-2. View

13.

Ostuzzi G, Bertolini F, Tedeschi F, Vita G, Brambilla P, Del Fabro L . Oral and long-acting antipsychotics for relapse prevention in schizophrenia-spectrum disorders: a network meta-analysis of 92 randomized trials including 22,645 participants. World Psychiatry. 2022; 21(2):295-307. PMC: 9077618. DOI: 10.1002/wps.20972. View

14.

Velligan D, Weiden P, Sajatovic M, Scott J, Carpenter D, Ross R . The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness. J Clin Psychiatry. 2009; 70 Suppl 4:1-46. View

15.

Goldstone L . Unmet medical needs and other challenges in the treatment of patients with schizophrenia. Am J Manag Care. 2020; 26(3 Suppl):S48-S54. DOI: 10.37765/ajmc.2020.43011. View

16.

Arango C, Baeza I, Bernardo M, Canas F, Dios C, Diaz-Marsa M . Long-acting injectable antipsychotics for the treatment of schizophrenia in Spain. Rev Psiquiatr Salud Ment (Engl Ed). 2018; 12(2):92-105. DOI: 10.1016/j.rpsm.2018.03.006. View

17.

Rubio J, Mychaskiw M, Lim S, Suett M, Wang Y, Tian M . Predictors for Initiation of Atypical Long-Acting Injectable Antipsychotic Agents in a Commercial Claims Cohort of Individuals With Early-Phase Schizophrenia. J Clin Psychiatry. 2023; 84(2). DOI: 10.4088/JCP.22m14604. View

18.

Tiihonen J, Haukka J, Taylor M, Haddad P, Patel M, Korhonen P . A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. Am J Psychiatry. 2011; 168(6):603-9. DOI: 10.1176/appi.ajp.2011.10081224. View

19.

Patel K, Cherian J, Gohil K, Atkinson D . Schizophrenia: overview and treatment options. P T. 2014; 39(9):638-45. PMC: 4159061. View

20.

Schoeler T, Petros N, Di Forti M, Klamerus E, Foglia E, Murray R . Poor medication adherence and risk of relapse associated with continued cannabis use in patients with first-episode psychosis: a prospective analysis. Lancet Psychiatry. 2017; 4(8):627-633. PMC: 5522816. DOI: 10.1016/S2215-0366(17)30233-X. View